Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice

American Journal of Medicine

Volumn 130, Issue 2, 2017, Pages 135-145

  Mazurek, Michał ^a,b   Huisman, Menno V ^c   Lip, Gregory Y H ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Antithrombotic treatment; Atrial fibrillation; Registry; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ASIA; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; EUROPE; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MORTALITY; NORTH AMERICAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REGISTER; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION; COMPLICATION; STROKE;

ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; REGISTRIES; STROKE;

EID: 85008260103     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.09.012     Document Type: Review

References (86)

1. 1 Taillandier, S., Olesen, J.B., Clémenty, N., et al. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study. J Cardiovasc Electrophysiol 23 (2012), 708–713.
2. 2 Lip, G.Y.H., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J.G.M., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
3. 3 Lip, G.Y.H., Lane, D.A., Stroke prevention in atrial fibrillation: a systematic review. JAMA 313 (2015), 1950–1962.
4. 4 Lip, G.Y.H., Skjoth, F., Nielsen, P.B., Larsen, T.B., Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 114 (2015), 826–834.
5. 5 Chao, T.-F., Liu, C.-J., Wang, K.-L., et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 65 (2015), 635–642.
6. 6 Lip, G.Y.H., Nielsen, P.B., Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated?: yes: even 1 stroke risk factor confers a real risk of stroke. Circulation 133 (2016), 1498–1503.
7. 7 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
8. 8 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
9. 9 Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
10. 10 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
11. 11 Olesen, J.B., Lip, G.Y.H., Hansen, M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 342, 2011, d124.
12. 12 Friberg, L., Skeppholm, M., Terént, A., Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 65 (2015), 225–232.
13. 13 Staerk, L., Lip, G.Y.H., Olesen, J.B., et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 351, 2015, h5876.
14. 14 Lip, G.Y.H., EUR Observational research programme: atrial fibrillation general registry pilot phase. Eur Heart J, 34, 2013, 794.
15. 15 Akao, M., Chun, Y.-H., Wada, H., et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61 (2013), 260–266.
16. 16 Akao, M., Chun, Y.-H., Esato, M., et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 78 (2014), 2166–2172.
17. 17 Huisman, M.V., Lip, G.Y.H., Diener, H.C., et al. Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 167 (2014), 329–334.
18. 18 Kakkar, A.K., Mueller, I., Bassand, J.P., et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 163 (2012), 13–19.e1.
19. 19 Piccini, J.P., Fraulo, E.S., Ansell, J.E., et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 162 (2011), 606–612.
20. 20 Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Origasa, H., Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation-The J-RHYTHM Registry study design. J Cardiol 57 (2011), 95–99.
21. 21 Chan, P.S., Oetgen, W.J., Buchanan, D., et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol 56 (2010), 8–14.
22. 22 Lewis, W.R., Piccini, J.P., Turakhia, M.P., et al. Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 7 (2014), 770–777.
23. 23 Steg, P.G., Alam, S., Chiang, C.-E., et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98 (2011), 195–201.
24. 24 Gamra, H., Murin, J., Chiang, C.E., Naditch-Brûlé, L., Brette, S., Steg, P.G., Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 107 (2014), 77–87.
25. 25 Nieuwlaat, R., Capucci, A., Camm, A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005), 2422–2434.
26. 26 Nieuwlaat, R., Capucci, A., Lip, G.Y.H., et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27 (2006), 3018–3026.
27. 27 Fuster, V., Rydén, L.E., Asinger, R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guide. Eur Heart J 22 (2001), 1852–1923.
28. 28 Jackson, S.L., Peterson, G.M., Vial, J.H., Daud, R., Ang, S.Y., Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J 31 (2001), 329–336.
29. 29 Laguna, P., Martn, A., del Arco, C., Gargantilla, P., Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann Emerg Med 44 (2004), 3–11.
30. 30 Nieuwlaat, R., Olsson, S.B., Lip, G.Y.H., et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 153 (2007), 1006–1012.
31. 31 Nieuwlaat, R., Dinh, T., Olsson, S.B., et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. Eur Heart J 29 (2008), 915–922.
32. 32 Dagres, N., Nieuwlaat, R., Vardas, P.E., et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 49 (2007), 572–577.
33. 33 Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J.G.M., Lip, G.Y.H., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
34. 34 Banerjee, A., Marín, F., Lip, G.Y.H., The improved but unfinished business of stroke risk stratification in atrial fibrillation. Rev Esp Cardiol 64 (2011), 639–641.
35. 35 Camm, A.J., Lip, G.Y.H., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.
36. 36 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130 (2014), e199–e267.
37. 37 Atrial fibrillation: the management of atrial fibrillation. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25340239. Accessed December 12, 2015.
38. 38 Lip, G.Y.H., Laroche, C., Dan, G.A., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16 (2014), 308–319.
39. 39 Lip, G.Y.H., Laroche, C., Dan, G.A., et al. “Real-world” antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med 127 (2014), 519–529.e1.
40. 40 Lip, G.Y.H., Laroche, C., Popescu, M.I., et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 17 (2015), 1777–1786.
41. 41 Lip, G.Y.H., Laroche, C., Ioachim, P.M., et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 35 (2014), 3365–3376.
42. 42 Nieuwlaat, R., Prins, M.H., Le Heuzey, J.-Y., et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 29 (2008), 1181–1189.
43. 43 Chan, P.S., Maddox, T.M., Tang, F., Spinler, S., Spertus, J.A., Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol 108 (2011), 1136–1140.
44. 44 Hsu, J.C., Chan, P.S., Tang, F., Maddox, T.M., Marcus, G.M., Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med 128 (2015), 654.e1–654.e10.
45. 45 Hsu, J.C., Chan, P.S., Tang, F., Maddox, T.M., Marcus, G.M., Oral anticoagulant prescription in patients with atrial fibrillation and a low risk of thromboembolism: insights from the NCDR PINNACLE Registry. JAMA Intern Med 175 (2015), 1062–1065.
46. 46 Siu, C.-W., Lip, G.Y.H., Lam, K.-F., Tse, H.-F., Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 11 (2014), 1401–1408.
47. 47 Wang, C., Yang, Z., Wang, C., et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China National Stroke Registry. J Stroke Cerebrovasc Dis 23 (2014), 1157–1163.
48. 48 Yang, X., Li, Z., Zhao, X., et al. Use of warfarin at discharge among acute ischemic stroke patients with nonvalvular atrial fibrillation in China. Stroke 47 (2016), 464–470.
49. 49 Kim, W.J., Park, J.M., Kang, K., et al. Adherence to guidelines for antithrombotic therapy in patients with atrial fibrillation according to CHADS2 Score before and after stroke: a multicenter observational study from Korea. J Clin Neurol 12 (2016), 34–41.
50. 50 Chen, P.-C., Lip, G.Y.H., Yeh, G., Lin, H.-J., Chien, K.-L., Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One, 10, 2015, e0125257.
51. 51 Huang, D., Anguo, L., Yue, W.-S., Yin, L., Tse, H.-F., Siu, C.-W., Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1. Pacing Clin Electrophysiol 37 (2014), 1442–1447.
52. 52 Chao, T.-F., Liu, C.-J., Chen, S.-J., et al. Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?. Stroke 43 (2012), 2551–2555.
53. 53 Siu, C.-W., Tse, H.-F., Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol 7 (2014), 300–306.
54. 54 Chen, T., Yang, Y.-M., Tan, H.-Q., Liang, Y., Zhu, J., Baseline characteristics and 1-year follow-up of Chinese atrial fibrillation patients according to age: a registry study. Pacing Clin Electrophysiol 37 (2014), 1392–1403.
55. 55 Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-. Circ J 75 (2011), 2357–2362.
56. 56 Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N., Origasa, H., Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 75 (2011), 1328–1333.
57. 57 Inoue, H., Okumura, K., Atarashi, H., et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 77 (2013), 2264–2270.
58. 58 Huisman, M.V., Ma, C.S., Diener, H.-C., et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace 18 (2016), 1308–1318.
59. 59 Huisman, M.V., Rothman, K.J., Paquette, M., et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, phase II. Am J Med 128 (2015), 1306–1313.e1.
60. 60 Kakkar, A.K., Mueller, I., Bassand, J.-P., et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One, 8, 2013, e63479.
61. 61 Kakkar AK (2015, August). Anticoagulation and AF: real life data from the GARFIELD-AF registry. In: Symposium Conducted at ESC Congress 2015, London, United Kingdom. Available at: http://congress365.escardio.org/Session/16231#.WBO9MMm_Gy4.
62. 62 Bassand, J.-P., Accetta, G., Camm, A.J., et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 37 (2016), 2882–2889.
63. 63 Kirchhof, P., Ammentorp, B., Darius, H., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 16 (2014), 6–14.
64. 64 Steinberg, B.A., Kim, S., Thomas, L., et al. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 129 (2014), 2005–2012.
65. 65 De Caterina, R., Ammentorp, B., Darius, H., et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 100 (2014), 1625–1635.
66. 66 Fosbol, E.L., Holmes, D.N., Piccini, J.P., et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc, 2, 2013, e000110.
67. 67 Camm, A.J., Pinto, F.J., Hankey, G.J., Andreotti, F., Hobbs, F.D.R., Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 17 (2015), 1007–1017.
68. 68 Lewis, W.R., Fonarow, G.C., Grau-Sepulveda, M.V., et al. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. Am Heart J 162 (2011), 692–699.e2.
69. 69 Hamatani, Y., Yamashita, Y., Esato, M., et al. Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation: the Fushimi AF Registry. PLoS One, 10, 2015, e0142394.
70. 70 Yamashita, Y., Hamatani, Y., Esato, M., et al. Low body weight is associated with the incidence of stroke in atrial fibrillation patients - insight from the Fushimi AF Registry. Circ J 79 (2015), 1009–1017.
71. 71 Suzuki, S., Yamashita, T., Okumura, K., et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy–pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J 79 (2015), 432–438.
72. 72 O'Brien, E.C., Holmes, D.N., Ansell, J.E., et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 167 (2014), 601–609.e1.
73. 73 O'Brien, E.C., Simon, D.N., Allen, L.A., et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 168 (2014), 487–494.
74. 74 Schwamm, L.H., Fonarow, G.C., Reeves, M.J., et al. Get with the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119 (2009), 107–115.
75. 75 Lewis, W.R., Fonarow, G.C., LaBresh, K.A., et al. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol 103 (2009), 227–231.
76. 76 Hess, C.N., Peterson, E.D., Peng, S.A., et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol 66 (2015), 616–627.
77. 2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J 78 (2014), 1593–1599.
78. 78 Tomita, H., Okumura, K., Inoue, H., et al. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation – subanalysis of the J-RHYTHM Registry. Circ J 79 (2015), 1719–1726.
79. 79 Yamashita, Y., Hamatani, Y., Esato, M., et al. Clinical characteristics and outcomes in extreme elderly (age ≥85) Japanese patients with atrial fibrillation: the Fushimi AF Registry. Chest 149 (2016), 401–412.
80. 80 Chao, T.-F., Wang, K.-L., Liu, C.-J., et al. Age threshold for increased stroke risk among patients with atrial fibrillation. J Am Coll Cardiol 66 (2015), 1339–1347.
81. 81 Camm, A.J., Kirchhof, P., Lip, G.Y.H., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12 (2010), 1360–1420.
82. 82 Le Heuzey, J.Y., Ammentorp, B., Darius, H., et al. Differences among western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF Registry. Thromb Haemost 111 (2014), 833–841.
83. 83 Steinberg, B.A., Kim, S., Piccini, J.P., et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation 128 (2013), 721–728.
84. 84 Steinberg, B.A., Holmes, D.N., Piccini, J.P., et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc, 2, 2013, e000535.
85. 85 Freeman, J.V., Simon, D.N., Go, A.S., et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 8 (2015), 393–402.
86. 86 Steinberg, B.A., Blanco, R.G., Ollis, D., et al. Outcomes registry for better informed treatment of atrial fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J 168 (2014), 160–167.